A Phase 1b/2 Study of XL184 with or without Erlotinib in Subjects with Non-Small Cell Lung Cancer (XL184-202).

Trial Profile

A Phase 1b/2 Study of XL184 with or without Erlotinib in Subjects with Non-Small Cell Lung Cancer (XL184-202).

Completed
Phase of Trial: Phase I/II

Latest Information Update: 01 May 2017

At a glance

  • Drugs Cabozantinib (Primary) ; Erlotinib
  • Indications Non-small cell lung cancer
  • Focus Adverse reactions; Pharmacodynamics; Pharmacokinetics; Therapeutic Use
  • Sponsors Exelixis
  • Most Recent Events

    • 18 Sep 2013 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 30 Aug 2012 Planned End Date changed from 1 Jul 2011 to 1 Dec 2012 as reported by ClinicalTrials.gov.
    • 21 Feb 2011 Status changed from recruiting to active, no longer recruiting as reported by M.D. Anderson Cancer Center.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top